Sanofi Says Genzyme Integration Is On Track, But Fabrazyme Production Won't Meet Goals
This article was originally published in The Pink Sheet Daily
Full production of the rare disease drug is pushed back a quarter, but analysts warm to Sanofi's full-year guidance and ability to meet overall goals for R&D and Genzyme integration.
You may also be interested in...
The subsidiary of Sanofi long has pegged opening of additional plant as critical to restoring full production of Fabrazyme, which has been rationed to Fabry disease patients since a manufacturing interruption in 2009.
U.K biotech Oxyrane raises $26.5 million D round to advance enzyme replacement therapies and validate a technology platform that may lead to cheaper-to-produce and more effective ERTs
With product sales growth that most big pharmas can only dream of, Shire's specialist model is working.